Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan

Reuters11-18

Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan

Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera (zanidatamab-hrii), pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&D investments while maintaining disciplined capital allocation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577534-en) on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584983049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584983049","market":"us","top_or_hot":-1,"title":"Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera (zanidatamab-hrii), pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&amp;D investments while maintaining disciplined capital allocation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577534-en) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera (zanidatamab-hrii), pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&amp;D investments while maintaining disciplined capital allocation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577534-en) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8ryH2X:1","article_id":"2584983049","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584983049","pubTimestamp":1763445627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan. Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera , pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&D investments while maintaining disciplined capital allocation.Disclaimer: This news","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ZYME":"ZYMEWORKS INC (US)","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"Zymeworks Inc.宣布战略举措，通过多元化创收资产、资本配置和1.25亿美元的股票回购计划来优化未来现金流","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":0.9,"NDAQ":0.9},"content_text":"Zymeworks Inc. Announces Strategic Initiative to Optimize Future Cash Flows Through Diversified Revenue-Generating Assets, Capital Allocation, and $125 Million Share Repurchase Plan\n    \n\n        Zymeworks Inc. announced a new strategic initiative focused on optimizing future cash flows from its licensed products, including Ziihera (zanidatamab-hrii), pasritamig, and other healthcare assets. The company plans to build a diversified portfolio of revenue-generating assets by combining internal innovation, licensing, and strategic acquisitions. Zymeworks aims to reinvest proceeds from its royalty streams into assets with lower traditional biotechnology risk profiles and return excess capital to shareholders through share repurchase programs or special dividends. The company also authorized a new $125 million share repurchase plan and will continue to seek financial contributions from partnerships and collaborations to support ongoing R&D investments while maintaining disciplined capital allocation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9577534-en) on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584983049","isCrawlerRequest":true}